ArticleKidney international reports2025
Risk Factors for Disease Progression for Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN).
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07785739 (Assessment of a Clinical Prediction Model for Disease Progression in Patients With Primary Membranous Nephropathy), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of a Clinical Prediction Model for Disease Progression in Patients With Primary Membranous Nephropathy: A Prospective Observational Study
Who cites it
2 citing papers in PubMed.
- Risk stratification guided treatment and outcomes of pediatric membranous nephropathy.Pediatric nephrology (Berlin, Germany) · 2026Observational
- KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Introduction: Primary membranous nephropathy (pMN) is a frequent cause of nephrotic syndrome in adult patients without diabetes. Recognizing the major shift in the classification of pMN based on target antigen and the management of patients with pMN with more widespread use of rituximab (RTX), we sought to better characterize the clinical course and risk factors in adults and children with pMN. Methods: We used the Cure Glomerulonephropathy (CureGN) prospective cohort of patients with pMN diagnosed using biopsy between 2010 and 2023. We report time to kidney outcomes using adjusted Cox proportional hazards models. Results: In total, 591 patients (537 adults and 54 children) were evaluated with 9% reaching kidney failure. Anti-B cell therapy was used in 44% of patients. Age < 18 years, self-reported Black/African American race, proteinuria > 3 g/g, and lower estimated glomerular filtration rate (eGFR) at enrollment were associated with worse kidney survival. Black race (adjusted hazard ratio [HR]: 1.8; 95% confidence interval [CI]: 1.1-2.9) and age < 18 years (adjusted HR: 3.7; 95% CI: 2.0-7.1) were associated with an increased risk of kidney failure and/or > 40% eGFR decline after adjusting for exposure to immunosuppression. Latinx ethnicity was associated with a lower likelihood of reaching complete proteinuria remission (adjusted HR: 0.4; 95% CI: 0.2-0.7). Conclusion: This study unveils self-reported Black race, young age (aged < 18 years) and Latinx ethnicity as potential risk factors associated with worse kidney outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.